Evidence of low quality suggests that lactoferrin supplementation to enteral feeds with or without probiotics decreases late-onset sepsis and NEC stage II or III in preterm infants without adverse effects .
BACKGROUND Lactoferrin , a normal component of human colostrum and milk , can enhance host defenses and may be effective for prevention of sepsis and necrotizing enterocolitis ( NEC ) in preterm neonates .
To assess the safety and effectiveness of lactoferrin supplementation to enteral feeds for prevention of sepsis and NEC in preterm neonates Secondary objectives 1 .
To determine the effects of lactoferrin supplementation to enteral feeds to prevent neonatal sepsis and /or NEC on duration of positive-pressure ventilation , development of chronic lung disease ( CLD ) or periventricular leukomalacia ( PVL ) , length of hospital stay to discharge among survivors , and adverse neurological outcomes at two years of age or later2 .
To determine the adverse effects of lactoferrin supplementation for prophylaxis of neonatal sepsis and /or NECWhen data were available , we analyzed the following subgroups.1 .
Gestational age < 32 weeks and 32 to 36 weeks2 .
Type of feeding : breast milk versus formula milk SEARCH METHODS : We used the search strategy of the Cochrane Neonatal Review Group ( CNRG ) to up date our search in December 2016 .
Phase I trial of oral talactoferrin alfa in refractory solid tumors
Summary Background : Lactoferrin is an iron-binding glycoprotein first identified in breast milk as a protein product of mammary epithelial cells . Its immunomodulatory functions include activation of NK and lymphokine-activated killer cells and enhancement of PMN and macrophage cytotoxicity . Studies in animal models have shown promising anti-cancer activity . The purpose of the present study was to evaluate the safety and tolerability of talactoferrin alfa ( talactoferrin ; TLF ) in humans , as well as pharmacokinetics and pharmacodynamics . Methods : Ten adult patients with progressive advanced solid tumors who had failed conventional chemotherapy  were administered oral TLF at doses from 1.5 to 9 g/day , using a 2 weeks on , 2 weeks off schedule . Patients were evaluated for drug toxicity , tumor growth rate , talactoferrin pharmacokinetics and cytokine markers . Results : Talactoferrin was very well tolerated . No hematological , hepatic , or renal toxicities were reported . A single patient had Grade 2 diarrhea , and there were no Grade 3 or 4 toxicities . Following oral administration , significant levels of talactoferrin  were undetectable in circulation , but a statistically significant increase in circulating IL-18 , a pharmacodynamic indicator of talactoferrin activity , was observed . Of the eight patients who were radiologically evaluable , five ( 63 % ) had stable disease by RECIST criteria two months after start of therapy , including one patient with a minor response . Seven patients ( 88 % ) had a decrease in their tumor growth rate . The three patients with non-small cell lung cancer ( NSCLC ) all survived for at least one year following the start of talactoferrin monotherapy . Conclusions : Talactoferrin is a promising , well-tolerated new agent that should be evaluated further in patients with refractory metastatic cancer
Evidence of low quality suggests that lactoferrin supplementation to enteral feeds with or without probiotics decreases late-onset sepsis and NEC stage II or III in preterm infants without adverse effects .
BACKGROUND Lactoferrin , a normal component of human colostrum and milk , can enhance host defenses and may be effective for prevention of sepsis and necrotizing enterocolitis ( NEC ) in preterm neonates .
To assess the safety and effectiveness of lactoferrin supplementation to enteral feeds for prevention of sepsis and NEC in preterm neonates Secondary objectives 1 .
To determine the effects of lactoferrin supplementation to enteral feeds to prevent neonatal sepsis and /or NEC on duration of positive-pressure ventilation , development of chronic lung disease ( CLD ) or periventricular leukomalacia ( PVL ) , length of hospital stay to discharge among survivors , and adverse neurological outcomes at two years of age or later2 .
To determine the adverse effects of lactoferrin supplementation for prophylaxis of neonatal sepsis and /or NECWhen data were available , we analyzed the following subgroups.1 .
Gestational age < 32 weeks and 32 to 36 weeks2 .
Type of feeding : breast milk versus formula milk SEARCH METHODS : We used the search strategy of the Cochrane Neonatal Review Group ( CNRG ) to up date our search in December 2016 .